Journal of Molecular and Cellular Cardiology
Volume 49, Issue 4 , Pages 543-553 , October 2010

The pathophysiological mechanism underlying Brugada syndrome: Depolarization versus repolarization

  • Arthur A.M. Wilde

      Affiliations

    • Department of Cardiology, Academic Medical Center Amsterdam, Amsterdam, The Netherlands
    • ,
  • Pieter G. Postema

      Affiliations

    • Department of Cardiology, Academic Medical Center Amsterdam, Amsterdam, The Netherlands
    • ,
  • José M. Di Diego

      Affiliations

    • Masonic Medical Research Laboratory, Utica, NY, USA
    • ,
  • Sami Viskin

      Affiliations

    • Department of Cardiology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel
    • ,
  • Hiroshi Morita

      Affiliations

    • Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
    • ,
  • Jeffrey M. Fish

      Affiliations

    • Masonic Medical Research Laboratory, Utica, NY, USA
    • ,
  • Charles Antzelevitch

      Affiliations

    • Masonic Medical Research Laboratory, Utica, NY, USA
    • Corresponding Author InformationCorresponding author. Masonic Medical Research Laboratory, 2150 Bleecker Street, Utica, NY 13501, USA. Tel.: +1 315 735 2217; fax: +1 315 735 5648.

Received 4 June 2010 ,Revised 13 July 2010 ,Accepted 19 July 2010.

References 

  1. Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. J Am Coll Cardiol. 1992;20:1391–1396
  2. Antzelevitch C, Brugada P, Borggrefe M, Brugada J, Brugada R, Corrado D, et al. Brugada syndrome: report of the second consensus conference. Heart Rhythm. 2005;2:429–440
  3. Eckardt L, Probst V, Smits JP, Bahr ES, Wolpert C, Schimpf R, et al. Long-term prognosis of individuals with right precordial ST-segment-elevation Brugada syndrome. Circulation. 2005;111:257–263
  4. Priori SG, Napolitano C, Gasparini M, Pappone C, Della Bella P, Giordano U, et al. Natural history of Brugada syndrome: insights for risk stratification and management. Circulation. 2002;105:1342–1347
  5. Takagi M, Yokoyama Y, Aonuma K, Aihara N, Hiraoka M. Clinical characteristics and risk stratification in symptomatic and asymptomatic patients with brugada syndrome: multicenter study in Japan. J Cardiovasc Electrophysiol. 2007;18:1244–1251
  6. Postema PG, Wolpert C, Amin AS, Probst V, Borggrefe M, Roden DM, et al. Drugs and Brugada syndrome patients: review of the literature, recommendations, and an up-to-date website (www.brugadadrugs.org). Heart Rhythm. 2009;6:1335–1341
  7. Antzelevitch C. Brugada syndrome. Pacing Clin Electrophysiol. 2006;29:1130–1159
  8. Meregalli PG, Wilde AA, Tan HL. Pathophysiological mechanisms of Brugada syndrome: depolarization disorder, repolarization disorder, or more?. Cardiovasc Res. 2005;67:367–378
  9. Yan GX, Antzelevitch C. Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST-segment elevation. Circulation. 1999;100:1660–1666
  10. Corrado D, Nava A, Buja G, Martini B, Fasoli G, Oselladore L, et al. Familial cardiomyopathy underlies syndrome of right bundle branch block, ST segment elevation and sudden death. J Am Coll Cardiol. 1996;27:443–448
  11. Matsuo K, Shimizu W, Kurita T, Suyama K, Aihara N, Kamakura S, et al. Increased dispersion of repolarization time determined by monophasic action potentials in two patients with familial idiopathic ventricular fibrillation. J Cardiovasc Electrophysiol. 1998;9:74–83
  12. Tukkie R, Sogaard P, Vleugels J, de Groot I, Wilde AA, Tan HL. Delay in right ventricular activation contributes to Brugada syndrome. Circulation. 2004;109:1272–1277
  13. Kasanuki H, Ohnishi S, Ohtuka M, Matsuda N, Nirei T, Isogai R, et al. Idiopathic ventricular fibrillation induced with vagal activity in patients without obvious heart disease. Circulation. 1997;95:2277–2285
  14. Coronel R, Casini S, Koopmann TT, Wilms-Schopman FJ, Verkerk AO, de Groot JR, et al. Right ventricular fibrosis and conduction delay in a patient with clinical signs of Brugada syndrome: a combined electrophysiological, genetic, histopathologic, and computational study. Circulation. 2005;112:2769–2777
  15. Postema PG, van Dessel PF, de Bakker JM, Dekker LR, Linnenbank AC, Hoogendijk MG, et al. Slow and discontinuous conduction conspire in Brugada syndrome: a right ventricular mapping and stimulation study. Circ Arrhythm Electrophysiol. 2008;1:379–386
  16. Nagase S, Kusano KF, Morita H, Fujimoto Y, Kakishita M, Nakamura K, et al. Epicardial electrogram of the right ventricular outflow tract in patients with the Brugada syndrome: using the epicardial lead. J Am Coll Cardiol. 2002;39:1992–1995
  17. Hisamatsu K, Kusano KF, Morita H, Takenaka S, Nagase S, Nakamura K, et al. Relationships between depolarization abnormality and repolarization abnormality in patients with Brugada syndrome: using body surface signal-averaged electrocardiography and body surface maps. J Cardiovasc Electrophysiol. 2004;15:870–876
  18. Bruns HJ, Eckardt L, Vahlhaus C, Schulze-Bahr E, Haverkamp W, Borggrefe M, et al. Body surface potential mapping in patients with Brugada syndrome: right precordial ST segment variations and reverse changes in left precordial leads. Cardiovasc Res. 2002;54:58–66
  19. Postema PG, van Dessel PF, Kors JA, Linnenbank AC, van Herpen G, Ritsema van Eck HJ, et al. Local depolarization abnormalities are the dominant pathophysiologic mechanism for the type-1 ECG in Brugada syndrome. A study of electrocardiograms, vectorcardiograms and body surface potential maps during ajmaline provocation. J Am Coll Cardiol. 2010;55:789–797
  20. Rolf S, Bruns HJ, Wichter T, Kirchhof P, Ribbing M, Wasmer K, et al. The ajmaline challenge in Brugada syndrome: diagnostic impact, safety, and recommended protocol. Eur Heart J. 2003;24:1104–1112
  21. Meregalli PG, Ruijter JM, Hofman N, Bezzina CR, Wilde AA, Tan HL. Diagnostic value of flecainide testing in unmasking SCN5A-related Brugada syndrome. J Cardiovasc Electrophysiol. 2006;17:857–864
  22. Wolpert C, Echternach C, Veltmann C, Antzelevitch C, Thomas GP, Spehl S, et al. Intravenous drug challenge using flecainide and ajmaline in patients with Brugada syndrome. Heart Rhythm. 2005;2:254–260
  23. Brugada R, Brugada J, Antzelevitch C, Kirsch GE, Potenza D, Towbin JA, et al. Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts. Circulation. 2000;101:510–515
  24. Shimizu W, Antzelevitch C, Suyama K, Kurita T, Taguchi A, Aihara N, et al. Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome. J Cardiovasc Electrophysiol. 2000;11:1320–1329
  25. Chen Q, Kirsch GE, Zhang D, Brugada R, Brugada J, Brugada P, et al. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature. 1998;392:293–296
  26. Rook MB, Bezzina Alshinawi C, Groenewegen WA, van Gelder I, van Ginneken AC, Jongsma HJ, et al. Human SCN5A gene mutations alter cardiac sodium channel kinetics and are associated with the Brugada syndrome. Cardiovasc Res. 1999;44:507–517
  27. Fujiki A, Usui M, Nagasawa H, Mizumaki K, Hayashi H, Inoue H. ST segment elevation in the right precordial leads induced with class IC antiarrhythmic drugs: insight into the mechanism of Brugada syndrome. J Cardiovasc Electrophysiol. 1999;10:214–218
  28. Bebarova M, O'Hara T, Geelen JL, Jongbloed RJ, Timmermans C, Arens YH, et al. Subepicardial phase-0 block and discontinuous transmural conduction underlie right-precordial ST-segment elevation by a SCN5A loss-of-function mutation. Am J Physiol Heart Circ Physiol. 2008;295:H48–H58
  29. Frustaci A, Priori SG, Pieroni M, Chimenti C, Napolitano C, Rivolta I, et al. Cardiac histological substrate in patients with clinical phenotype of Brugada syndrome. Circulation. 2005;112:3680–3687
  30. Morita H, Kusano KF, Miura D, Nagase S, Nakamura K, Morita ST, et al. Fragmented QRS as a marker of conduction abnormality and a predictor of prognosis of Brugada syndrome. Circulation. 2008;118:1697–1704
  31. Chiale PA, Przybylski J, Laino RA, Halpern MS, Sanchez RA, Gabrieli A, et al. Electrocardiographic changes evoked by ajmaline in chronic Chagas' disease with manifest myocarditis. Am J Cardiol. 1982;49:14–20
  32. Bezzina CR, Rook MB, Groenewegen WA, Herfst LJ, van der Wal AC, Lam J, et al. Compound heterozygosity for mutations (W156X and R225W) in SCN5A associated with severe cardiac conduction disturbances and degenerative changes in the conduction system. Circ Res. 2003;92:159–168
  33. van Veen TA, Stein M, Royer A, Le Quang K, Charpentier F, Colledge WH, et al. Impaired impulse propagation in Scn5a-knockout mice: combined contribution of excitability, connexin expression, and tissue architecture in relation to aging. Circulation. 2005;112:1927–1935
  34. de Bakker JM, van Capelle FJ, Janse MJ, Tasseron S, Vermeulen JT, de Jonge N, et al. Slow conduction in the infarcted human heart. 'Zigzag' course of activation. Circulation. 1993;88:915–926
  35. Gaborit N, Wichter T, Varro A, Szuts V, Lamirault G, Eckardt L, et al. Transcriptional profiling of ion channel genes in Brugada syndrome and other right ventricular arrhythmogenic diseases. Eur Heart J. 2009;30:487–496
  36. Probst V, Wilde AA, Barc J, Sacher F, Babuty D, Mabo P, et al. SCN5A mutations and the role of genetic background in the pathophysiology of Brugada syndrome. Circ Cardiovasc Genet. 2009;2:552–557
  37. Tan HL, Bezzina CR, Smits JP, Verkerk AO, Wilde AA. Genetic control of sodium channel function. Cardiovasc Res. 2003;57:961–973
  38. Amin AS, Meregalli PG, Bardai A, Wilde AA, Tan HL. Fever increases the risk for cardiac arrest in the Brugada syndrome. Ann Intern Med. 2008;149:216–218
  39. Franz MR, Bargheer K, Rafflenbeul W, Haverich A, Lichtlen PR. Monophasic action potential mapping in human subjects with normal electrocardiograms: direct evidence for the genesis of the T wave. Circulation. 1987;75:379–386
  40. Hoogendijk MG, Potse M, Linnenbank AC, Verkerk AO, Den Ruijter HM, Van Amersfoorth SC, et al. Mechanism of right precordial ST-segment elevation in structural heart disease: excitation failure by current-to-load mismatch. Heart Rhythm. 2010;7:238–248
  41. Rohr S, Salzberg BM. Characterization of impulse propagation at the microscopic level across geometrically defined expansions of excitable tissue: multiple site optical recording of transmembrane voltage (MSORTV) in patterned growth heart cell cultures. J Gen Physiol. 1994;104:287–309
  42. Gussak I, Antzelevitch C, Bjerregaard P, Towbin JA, Chaitman BR. The Brugada syndrome: clinical, electrophysiologic and genetic aspects. J Am Coll Cardiol. 1999;33:5–15
  43. Miyazaki T, Mitamura H, Miyoshi S, Soejima K, Aizawa Y, Ogawa S. Autonomic and antiarrhythmic drug modulation of ST segment elevation in patients with Brugada syndrome. J Am Coll Cardiol. 1996;27:1061–1070
  44. Antzelevitch C, Brugada P, Brugada J, Brugada R, Shimizu W, Gussak I, et al. Brugada syndrome: a decade of progress. Circ Res. 2002;91:1114–1118
  45. Kurita T, Shimizu W, Inagaki M, Suyama K, Taguchi A, Satomi K, et al. The electrophysiologic mechanism of ST-segment elevation in Brugada syndrome. J Am Coll Cardiol. 2002;40:330–334
  46. Aiba T, Shimizu W, Hidaka I, Uemura K, Noda T, Zheng C, et al. Cellular basis for trigger and maintenance of ventricular fibrillation in the brugada syndrome model high-resolution optical mapping study. J Am Coll Cardiol. 2006;47:2074–2085
  47. Di Diego JM, Cordeiro JM, Goodrow RJ, Fish JM, Zygmunt AC, Perez GJ, et al. Ionic and cellular basis for the predominance of the Brugada syndrome phenotype in males. Circulation. 2002;106:2004–2011
  48. Fish JM, Antzelevitch C. Role of sodium and calcium channel block in unmasking the Brugada syndrome. Heart Rhythm. 2004;1:210–217
  49. Morita H, Zipes DP, Fukushima-Kusano K, Nagase S, Nakamura K, Morita ST, et al. Repolarization heterogeneity in the right ventricular outflow tract: correlation with ventricular arrhythmias in Brugada patients and in an in vitro canine Brugada model. Heart Rhythm. 2008;5:725–733
  50. Shimizu W, Aiba T, Kamakura S. Mechanisms of disease: current understanding and future challenges in Brugada syndrome. Nat Clin Pract Cardiovasc Med. 2005;2:408–414
  51. Tan HL. Sodium channel variants in heart disease: expanding horizons. J Cardiovasc Electrophysiol. 2006;17(Suppl 1):S151–S157
  52. Zumhagen S, Spieker T, Rolinck J, Baba HA, Breithardt G, Bocker W, et al. Absence of pathognomonic or inflammatory patterns in cardiac biopsies from patients with Brugada syndrome. Circ Arrhythm Electrophysiol. 2009;2:16–23
  53. Antzelevitch C. Late potentials and the Brugada syndrome. J Am Coll Cardiol. 2002;39:1996–1999
  54. Eckardt L, Bruns HJ, Paul M, Kirchhof P, Schulze-Bahr E, Wichter T, et al. Body surface area of ST elevation and the presence of late potentials correlate to the inducibility of ventricular tachyarrhythmias in Brugada syndrome. J Cardiovasc Electrophysiol. 2002;13:742–749
  55. Futterman LG, Lemberg L. Brugada. Am J Crit Care. 2001;10:360–364
  56. Ikeda T, Takami M, Sugi K, Mizusawa Y, Sakurada H, Yoshino H. Noninvasive risk stratification of subjects with a Brugada-type electrocardiogram and no history of cardiac arrest. Ann Noninvasive Electrocardiol. 2005;10:396–403
  57. Mizobuchi M, Enjoji Y, Nakamura S, Muranishi H, Utsunomiya M, Funatsu A, et al. Ventricular late potential in patients with apparently normal electrocardiogram; predictor of Brugada syndrome. Pacing Clin Electrophysiol. 2010;33(3):266–273
  58. Takagi M, Aihara N, Kuribayashi S, Taguchi A, Shimizu W, Kurita T, et al. Localized right ventricular morphological abnormalities detected by electron-beam computed tomography represent arrhythmogenic substrates in patients with the Brugada syndrome. Eur Heart J. 2001;22:1032–1041
  59. Antzelevitch C. Brugada syndrome: historical perspectives and observations. Eur Heart J. 2002;23:676–678
  60. Esperer HD, Hoos O, Hottenrott K. Syncope due to Brugada syndrome in a young athlete. Br J Sports Med. 2006;41:180–181
  61. Guevara-Valdivia ME, Iturralde TP, De MA, Colin LL, Medeiros DA, Gonzalez-Hermosillo JA. Electrocardiographic changes during stress test in a patient with "Brugada syndrome". Arch Cardiol Méx. 2001;71:66–72
  62. Stix G, Bella PD, Carbucicchio C, Schmidinger H. Spatial and temporal heterogeneity of depolarization and repolarization may complicate implantable cardioverter defibrillator therapy in Brugada syndrome. J Cardiovasc Electrophysiol. 2000;11:516–521
  63. Amin AS, de Groot EA, Ruijter JM, Wilde AA, Tan HL. Exercise-induced ECG changes in Brugada syndrome. Circ Arrhythm Electrophysiol. 2009;2:531–539
  64. Belhassen B, Glick A, Viskin S. Efficacy of quinidine in high-risk patients with Brugada syndrome. Circulation. 2004;110:1731–1737
  65. Belhassen B, Viskin S. Pharmacologic approach to therapy of Brugada syndrome: quinidine as an alternative to ICD therapy?. In:  Antzelevitch C,  Brugada P,  Brugada J,  Brugada R editor. The Brugada syndrome: from bench to bedside. Oxford: Blackwell Futura; 2004;p. 202–211
  66. Watanabe H, Chinushi M, Osaki A, Okamura K, Izumi D, Komura S, et al. Elimination of late potentials by quinidine in a patient with Brugada syndrome. J Electrocardiol. 2006;39:63–66
  67. Di Diego JM, Antzelevitch C. Cellular basis for ST-segment changes observed during ischemia. J Electrocardiol. 2003;36(Suppl):1–5
  68. Di Diego JM, Fish JM, Antzelevitch C. Brugada syndrome and ischemia-induced ST-segment elevation. Similarities and differences. J Electrocardiol. 2005;38:14–17
  69. Childers R. R wave amplitude in ischemia, injury, and infarction. Plenary address. J Electrocardiol. 1996;29(Suppl):171–178
  70. Cordeiro JM, Mazza M, Goodrow R, Ulahannan N, Antzelevitch C, Di Diego JM. Functionally distinct sodium channels in ventricular epicardial and endocardial cells contribute to a greater sensitivity of epicardium to electrical depression. Am J Physiol Heart Circ Physiol. 2008;295:H154–H162
  71. Opthof T, Coronel R, Janse MJ, Rosen MR. A wedge is not a heart. Heart Rhythm. 2007;4:1116–1119
  72. Kanda M, Shimizu W, Matsuo K, Nagaya N, Taguchi A, Suyama K, et al. Electrophysiologic characteristics and implications of induced ventricular fibrillation in symptomatic patients with Brugada syndrome. J Am Coll Cardiol. 2002;39:1799–1805
  73. Morita H, Takenaka-Morita S, Fukushima-Kusano K, Kobayashi M, Nagase S, Kakishita M, et al. Risk stratification for asymptomatic patients with Brugada syndrome. Circ J. 2003;67:312–316
  74. Fazelifar AF, Haghjoo M, Arya A, Kazemi B, Bagherzadeh A, Nikoo MH, et al. Spontaneous alternans in Brugada ECG morphology. J Interv Card Electrophysiol. 2006;15:131–134
  75. Tada H, Nogami A, Shimizu W, Naito S, Nakatsugawa M, Oshima S, et al. ST segment and T wave alternans in a patient with Brugada syndrome. Pacing Clin Electrophysiol. 2000;23:413–415
  76. Tada T, Kusano KF, Nagase S, Banba K, Miura D, Nishii N, et al. Clinical significance of macroscopic T-wave alternans after sodium channel blocker administration in patients with Brugada syndrome. J Cardiovasc Electrophysiol. 2008;19:56–61
  77. Morita H, Nagase S, Miura D, Miura A, Hiramatsu S, Tada T, et al. Differential effects of cardiac sodium channel mutations on initiation of ventricular arrhythmias in patients with Brugada syndrome. Heart Rhythm. 2009;6:487–492
  78. Calloe K, Cordeiro JM, Di Diego JM, Hansen RS, Grunnet M, Olesen SP, et al. A transient outward potassium current activator recapitulates the electrocardiographic manifestations of Brugada syndrome. Cardiovasc Res. Mar 1 2009;81(4):686–694
  79. Delpón E, Cordeiro JM, Núñez L, Thomsen PEB, Guerchicoff A, Pollevick GD, et al. Functional effects of KCNE3 mutation and its role in the development of Brugada syndrome. Circ Arrhythm Electrophysiol. 2008;1:209–218
  80. Makimoto H, Nakagawa E, Takaki H, Yamagata K, Kawata H, Okamura H, et al. Diagnostic and prognostic value of augmented ST-segment elevation at exercise testing in patients with Brugada syndrome. Circulation. 2008;118(Suppl 2):S674
  81. Fish JM, Antzelevitch C. Cellular mechanism and arrhythmogenic potential of T-wave alternans in the Brugada syndrome. J Cardiovasc Electrophysiol. Mar 2008;19(3):301–308
  82. In:  Antzelevitch C editors. The Brugada syndrome. From bench to bedside. Malden, MA: Blackwell, Futura; 2005;

☆ Supported by grant HL47678 (C.A.) from NHLBI, and New York State and Florida Grand Lodges of Free and Accepted Masons.

PII: S0022-2828(10)00276-2

doi: 10.1016/j.yjmcc.2010.07.012

Journal of Molecular and Cellular Cardiology
Volume 49, Issue 4 , Pages 543-553 , October 2010

Article Tools

* Image Usage & Resolution